«Direct one-step labeling of cysteine residues on peptides with [(11)C]methyl triflate for the synthesis of PET radiopharmaceuticals». Amino Acids45 (5): 1097–108. November 2013. doi:10.1007/s00726-013-1562-5. PMID23921782.
«Decreased leg glucose uptake during exercise contributes to the hyperglycaemic effect of octreotide». Clinical Physiology and Functional Imaging30 (2): 141–5. March 2010. doi:10.1111/j.1475-097X.2009.00917.x. PMID20132129.
«Inhibition of penile erection in rats by a long-acting somatostatin analogue, octreotide (SMS 201-995)». British Journal of Urology81 (1): 142–5. January 1998. doi:10.1046/j.1464-410x.1998.00520.x. PMID9467491.
«Design, synthesis and biological evaluation of 3-amino-3-phenylpropionamide derivatives as novel mu opioid receptor ligands». Bioorganic & Medicinal Chemistry Letters10 (6): 523–6. March 2000. doi:10.1016/s0960-894x(00)00034-2. PMID10741545.
«The role of octreotide and somatostatin in acute and chronic pancreatitis». Digestion60 Suppl 2 (2): 23–31. 1999. doi:10.1159/000051477. PMID10207228.
«Clinical efficacy and safety of octreotide (SMS201-995) in terminally ill Japanese cancer patients with malignant bowel obstruction». Japanese Journal of Clinical Oncology38 (5): 354–9. May 2008. doi:10.1093/jjco/hyn035. PMID18490369.
«Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome». Journal of Clinical Gastroenterology43 (7): 680–5. August 2009. doi:10.1097/MCG.0b013e318188947c. PMID19238094.
«Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial». The Journal of Clinical Endocrinology and Metabolism88 (6): 2586–92. June 2003. doi:10.1210/jc.2002-030003. PMID12788859.
«Direct one-step labeling of cysteine residues on peptides with [(11)C]methyl triflate for the synthesis of PET radiopharmaceuticals». Amino Acids45 (5): 1097–108. November 2013. doi:10.1007/s00726-013-1562-5. PMID23921782.
«Decreased leg glucose uptake during exercise contributes to the hyperglycaemic effect of octreotide». Clinical Physiology and Functional Imaging30 (2): 141–5. March 2010. doi:10.1111/j.1475-097X.2009.00917.x. PMID20132129.
«Inhibition of penile erection in rats by a long-acting somatostatin analogue, octreotide (SMS 201-995)». British Journal of Urology81 (1): 142–5. January 1998. doi:10.1046/j.1464-410x.1998.00520.x. PMID9467491.
«Design, synthesis and biological evaluation of 3-amino-3-phenylpropionamide derivatives as novel mu opioid receptor ligands». Bioorganic & Medicinal Chemistry Letters10 (6): 523–6. March 2000. doi:10.1016/s0960-894x(00)00034-2. PMID10741545.
«The role of octreotide and somatostatin in acute and chronic pancreatitis». Digestion60 Suppl 2 (2): 23–31. 1999. doi:10.1159/000051477. PMID10207228.
«Clinical efficacy and safety of octreotide (SMS201-995) in terminally ill Japanese cancer patients with malignant bowel obstruction». Japanese Journal of Clinical Oncology38 (5): 354–9. May 2008. doi:10.1093/jjco/hyn035. PMID18490369.
«Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome». Journal of Clinical Gastroenterology43 (7): 680–5. August 2009. doi:10.1097/MCG.0b013e318188947c. PMID19238094.
«Octreotide: a therapeutic option for idiopathic intracranial hypertension». Neurology, Neurophysiology, and Neuroscience: 1. July 2007. PMID17700925.
«Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial». The Journal of Clinical Endocrinology and Metabolism88 (6): 2586–92. June 2003. doi:10.1210/jc.2002-030003. PMID12788859.